- Market Radar
- /
- DRMA
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About DRMA
7/28/2025
Comprehensive Analysis
Financial Health
- Liquidity & Solvency: Dermata Therapeutics (DRMA) exhibits severe liquidity constraints, with a current ratio of 1.79 and quick ratio of 1.60 in 2024. Cash reserves have declined from $7.44B in 2023 to $3.16B in 2024, while operating cash flow remains negative at -$11.16B. Zero long-term debt reduces solvency risk, but reliance on financing activities (e.g., $6.2M warrant exercise in March 2025) highlights structural fragility.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing